Description: <b>Boswellia</b> is an herbal extract from the Boswellia serrata tree that may help reduce inflammation.<br>
May help with rheumatoid arthritis, inflammatory bowel disease, asthma, and cancer.<br>
-Naturally occurring pentacyclic triterpenoids include ursolic acid (UA), oleanolic acid (OA), betulinic acid (BetA), bosewellic acid (BA), Asiatic acid (AA), α-amyrin, celastrol, glycyrrhizin, 18-β-glycyrrhetinic acid, lupeol, escin, madecassic acid, momordin I, platycodon D, pristimerin, saikosaponins, soyasapogenol B, and avicin<br>
Boswellia refers to a group of resinous extracts obtained from Boswellia trees (e.g., Boswellia serrata). Traditionally used in Ayurvedic and traditional Chinese medicine, Boswellia is reputed for its anti-inflammatory, analgesic, and immunomodulatory properties. Its bioactive components—such as boswellic acids.<br>
Boswellic acids belong to the pentacyclic triterpenoid class (a broader chemical family that includes compounds such as ursolic acid and betulinic acid found in other plants)
<pre>
3-acetyl-11-keto-β-boswellic acid (AKBA)
11-keto-β-boswellic acid (KBA)
α-boswellic acid (αBA)
β-boswellic acid (βBA)
3-acetyl-α-boswellic acid (AαBA)
3-acetyl-β-boswellic acid (AβBA)
</pre>
-Anti-inflammatory Activity (blocking the enzyme 5-lipoxygenase)
<a href="tbResList.php?qv=47&tsv=1090&wNotes=on">5LOX↓</a>,.<br>
-AKBA inhibits
<a href="tbResList.php?qv=47&tsv=1206&wNotes=on">methionine adenosyltransferase 2A (MAT2A)</a>***** (help in Methionine reduced diet?)
<br>
Boswellia extracts are often administered in doses ranging from 300 mg to 1,200 mg per day<br>
<br>
AKBA (Acetyl-11-keto-β-boswellic acid) is a bioactive compound derived from Boswellia serrata, a plant used traditionally for its anti-inflammatory properties. (upto 30% AKBA in
<a href="https://www.mcsformulas.com/vitamins-supplements/boswellia-akba-liposomal/"> Boswellia MEGA AKBA</a>)<br>
AKBA also available in Inflasanum @ 90% AKDA (MCSformulas)<br>
<p><b>Boswellia (frankincense)</b> — Boswellia refers to oleo-gum-resin extracts from Boswellia species, most commonly <i>Boswellia serrata</i>, enriched in pentacyclic triterpenes known as boswellic acids. It is best classified as a botanical extract / natural-product mixture rather than a single drug entity, although much of the mechanistic cancer literature focuses on specific constituents such as 3-acetyl-11-keto-β-boswellic acid (AKBA) and 11-keto-β-boswellic acid (KBA). Standard abbreviations include Bos, BS, BA, KBA, and AKBA. The dominant translational theme is anti-inflammatory and anti-edema activity with broader preclinical anticancer signaling effects; however, extract composition, formulation, and exposure vary substantially across studies.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>5-lipoxygenase-linked leukotriene suppression and broader inflammatory eicosanoid downregulation</li>
<li>NF-κB pathway suppression with downstream reduction of COX-2, cytokines, survival factors, and pro-metastatic genes</li>
<li>Mitochondrial apoptosis and cell-cycle arrest in cancer models, including caspase activation, PARP cleavage, and cyclin/CDK suppression</li>
<li>PI3K/Akt, ERK/MAPK, STAT3, Wnt/β-catenin, and related growth-signaling attenuation</li>
<li>Anti-invasive / anti-angiogenic signaling, including MMP, VEGF, CXCR4, and EMT-related effects</li>
<li>MAT2A inhibition by AKBA with one-carbon / SAM metabolism disruption</li>
<li>Context-dependent redox modulation, with pro-apoptotic oxidative stress in some cancer models but antioxidant / NRF2-supportive effects reported in normal or inflamed tissues</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Boswellic acids are lipophilic and have poor oral bioavailability with marked formulation dependence. Human studies show food, especially a high-fat meal, substantially increases exposure, and reported half-life data are generally compatible with multi-hour persistence but not with reliably high systemic levels from standard extracts. Enhanced-delivery systems may improve exposure, but classic oral preparations remain PK-limited.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many mechanistic cancer studies use boswellic-acid concentrations in the roughly 10–50 µM range, which commonly exceed plasma exposure expected from standard oral Boswellia extracts. That makes direct translation of apoptosis, invasion, and signaling data uncertain unless high-exposure formulations, tissue accumulation, or local-compartment effects are demonstrated. Extract-level anti-inflammatory and edema effects are clinically more plausible than broad direct cytotoxic anticancer effects at routine oral dosing.</p>
<p><b>Clinical evidence status:</b> Cancer-directed evidence remains limited. There is meaningful human evidence for adjunctive anti-edema use during/after brain tumor irradiation and a small phase Ia presurgical breast-cancer window study showing reduced proliferation markers, but there is no established oncologic approval and no robust phase III anticancer efficacy program. Overall status is preclinical-heavy with small human adjunct / early translational signals.</p>
<br>
-Note <a href="tbResList.php?qv=47&tsv=1109&wNotes=on&exSp=open">half-life</a> reports vary 2.5-90hrs?.<br>
<a href="tbResList.php?qv=47&tsv=792&wNotes=on&exSp=open">BioAv</a> (bio availability increases with high fat meal)
<br>
Pathways:<br>
<!-- ROS : MMP↓, ER Stress↑, Ca+2↑, Cyt‑c↑, Casp3↑, Casp9↑, DNAdam↑, UPR↑, cl-PARP↑-->
- induce or lower
<a href="tbResList.php?qv=47&tsv=275&wNotes=on">ROS</a> production (not consistant increase for cancer cells)<br>
- ROS↑ related:
<a href="tbResList.php?qv=47&tsv=197&wNotes=on&word=MMP↓">MMP↓</a>(ΔΨm),
<a href="tbResList.php?qv=47&tsv=103&wNotes=on">ER Stress↑</a>,
<a href="tbResList.php?qv=47&tsv=356&wNotes=on">GRP78↑</a>,
<a href="tbResList.php?qv=47&tsv=38&wNotes=on&word=Ca+2↑">Ca+2↑</a>,
<a href="tbResList.php?qv=47&tsv=77&wNotes=on">Cyt‑c↑</a>,
<a href="tbResList.php?qv=47&wNotes=on&word=Casp">Caspases↑</a>,
<a href="tbResList.php?qv=47&tsv=82&wNotes=on&word=DNAdam↑">DNA damage↑</a>,
<a href="tbResList.php?qv=47&tsv=239&wNotes=on">cl-PARP↑</a>,
<br>
- may Raise
<a href="tbResList.php?qv=47&tsv=1103&wNotes=on&word=antiOx↑">AntiOxidant</a>
defense in Normal Cells:
<a href="tbResList.php?qv=47&tsv=275&wNotes=on&word=ROS↓">ROS↓</a>,
<a href="tbResList.php?qv=47&tsv=226&wNotes=on&word=NRF2↑">NRF2↑</a>,
<a href="tbResList.php?qv=47&tsv=298&wNotes=on&word=SOD↑">SOD↑</a>,
<a href="tbResList.php?qv=47&tsv=137&wNotes=on&word=GSH↑">GSH↑</a>,
<a href="tbResList.php?qv=47&tsv=46&wNotes=on&word=Catalase↑">Catalase↑</a>,
<br>
<!-- INFLAMMATION : NF-kB↓, COX2↓, COX2↓ PRO-INFL CYTOKINES: IL-1β↓, TNF-α↓, IL-6↓, IL-8↓, -->
- lowers
<a href="tbResList.php?qv=47&tsv=953&wNotes=on&word=Inflam">Inflammation</a> :
<a href="tbResList.php?qv=47&tsv=214&wNotes=on&word=NF-kB↓">NF-kB↓</a>,
<a href="tbResList.php?qv=47&tsv=66&wNotes=on&word=COX2↓">COX2↓</a>,
<a href="tbResList.php?qv=47&tsv=235&wNotes=on&word=p38↓">p38↓</a>
(context-dependent; stress/inflammatory MAPK modulation), Pro-Inflammatory Cytokines :
<a href="tbResList.php?qv=47&tsv=978&wNotes=on&word=IL1β↓">IL-1β↓</a>,
<a href="tbResList.php?qv=47&tsv=309&wNotes=on&word=TNF-α↓">TNF-α↓</a>,
<a href="tbResList.php?qv=47&tsv=158&wNotes=on&word=IL6↓">IL-6↓</a>,
<br>
<!-- GROWTH/METASTASES : EMT↓, MMPs↓, MMP2↓, MMP9↓, IGF-1, uPA↓, VEGF↓, ERK↓
inhibiting metastasis-associated proteins such as ROCK1, FAK, (RhoA), NF-κB and u-PA, MMP-1 and MMP-13.-->
- inhibit Growth/Metastases :
<a href="tbResList.php?qv=47&tsv=96&wNotes=on"EMT↓</a>,
<a href="tbResList.php?qv=47&tsv=204&wNotes=on">MMPs↓</a>,
<a href="tbResList.php?qv=47&tsv=201&wNotes=on">MMP2↓</a>,
<a href="tbResList.php?qv=47&tsv=203&wNotes=on">MMP9↓</a>,
<a href="tbResList.php?qv=47&tsv=334&wNotes=on">VEGF↓</a>,
<a href="tbResList.php?qv=47&tsv=214&wNotes=on">NF-κB↓</a>,
<a href="tbResList.php?qv=47&tsv=79&wNotes=on">CXCR4↓</a>,
<a href="tbResList.php?qv=47&tsv=105&wNotes=on">ERK↓</a>
<br>
<!-- CELL CYCLE ARREST : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓ -->
- cause Cell cycle arrest :
<a href="tbResList.php?qv=47&tsv=322&wNotes=on">TumCCA↑</a>,
<a href="tbResList.php?qv=47&tsv=73&wNotes=on">cyclin D1↓</a>,
<a href="tbResList.php?qv=47&tsv=378&wNotes=on">cyclin E↓</a>,
<a href="tbResList.php?qv=47&tsv=467&wNotes=on">CDK2↓</a>,
<a href="tbResList.php?qv=47&tsv=894&wNotes=on">CDK4↓</a>,
<a href="tbResList.php?qv=47&tsv=895&wNotes=on">CDK6↓</a>,
<br>
<!-- MIGRATION/INVASION : TumCMig↓, TumCI↓, FAK↓, ERK↓, -->
- inhibits Migration/Invasion :
<a href="tbResList.php?qv=47&tsv=326&wNotes=on">TumCMig↓</a>,
<a href="tbResList.php?qv=47&tsv=324&wNotes=on">TumCI↓</a>,
<a href="tbResList.php?qv=47&tsv=105&wNotes=on">ERK↓</a>,
<a href="tbResList.php?qv=47&tsv=1117&wNotes=on">TOP1↓</a>,
<br>
<!-- ANGIOGENESIS : VEGF↓, VEGFR2↓, HIF-1α↓, NOTCH↓, FGF↓, PDGF↓, EGFR↓ ITG(Integrins↓)-->
- inhibits
<a href="tbResList.php?qv=47&tsv=447&wNotes=on">angiogenesis↓</a> :
<a href="tbResList.php?qv=47&tsv=334&wNotes=on">VEGF↓</a>,
<a href="tbResList.php?qv=47&wNotes=on&word=NOTCH">Notch↓</a>,
<a href="tbResList.php?qv=47&tsv=361&wNotes=on">PDGF↓</a>,
<br>
<!-- OTHERS : -->
- Others: <a href="tbResList.php?qv=47&tsv=252&wNotes=on">PI3K↓</a>,
<a href="tbResList.php?qv=47&tsv=4&wNotes=on">AKT↓</a>,
<a href="tbResList.php?qv=47&wNotes=on&word=STAT">STAT↓</a>,
<a href="tbResList.php?qv=47&tsv=377&wNotes=on">Wnt↓</a>,
<a href="tbResList.php?qv=47&tsv=342&wNotes=on">β-catenin↓</a>,
<a href="tbResList.php?qv=47&tsv=9&wNotes=on">AMPK↓</a>,
<a href="tbResList.php?qv=47&tsv=105&wNotes=on">ERK↓</a>,
<a href="tbResList.php?qv=47&tsv=168&wNotes=on">JNK</a>(JNK is activated under stress)
<br>
<!-- SYNERGIES : -->
- Synergies:
<a href="tbResList.php?qv=47&tsv=1106&wNotes=on">chemo-sensitization</a>,
<a href="tbResList.php?qv=47&tsv=1171&wNotes=on">chemoProtective</a>,
<a href="tbResList.php?qv=47&tsv=1185&wNotes=on">RadioProtective</a>,
<a href="tbResList.php?qv=47&tsv=961&esv=2&wNotes=on&exSp=open">Others(review target notes)</a>,
<a href="tbResList.php?qv=47&tsv=1105&wNotes=on">Neuroprotective</a>,
<a href="tbResList.php?qv=47&tsv=557&wNotes=on">Cognitive</a>,
<a href="tbResList.php?qv=47&tsv=1179&wNotes=on">Hepatoprotective</a>,
<br>
<br>
<!-- SELECTIVE: -->
- Selectivity:
<a href="tbResList.php?qv=47&tsv=1110&wNotes=on">Cancer Cells vs Normal Cells</a><br>
<br>
<h3>Mechanistic profile</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>5-LOX eicosanoid signaling</td>
<td>↓ leukotriene-linked inflammatory drive</td>
<td>↓ inflammatory tone</td>
<td>P, R</td>
<td>Anti-inflammatory leverage</td>
<td>Most historically grounded Boswellia mechanism; strongest at extract / boswellic-acid anti-inflammatory level and likely central to edema-control relevance.</td>
</tr>
<tr>
<td>2</td>
<td>NF-κB inflammatory survival axis</td>
<td>↓ NF-κB, COX-2, TNF-α, IL-1β, IL-6, VEGF, MMPs</td>
<td>↓ inflammatory stress</td>
<td>R, G</td>
<td>Anti-survival transcriptional suppression</td>
<td>Supported across multiple tumor models; likely more translationally plausible as inflammation-modulating adjunct action than as stand-alone tumor cytotoxicity.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial apoptosis</td>
<td>↑ caspases, ↑ Cyt-c, ↓ MMP, ↑ cl-PARP</td>
<td>↔ / protective (context-dependent)</td>
<td>R, G</td>
<td>Programmed cell death</td>
<td>Common in AKBA-focused in-vitro studies; robust mechanistically, but often demonstrated at concentrations that may exceed routine oral exposure.</td>
</tr>
<tr>
<td>4</td>
<td>Cell-cycle control</td>
<td>↓ cyclin D1, ↓ cyclin E, ↓ CDK2/4/6, ↑ arrest</td>
<td>↔</td>
<td>G</td>
<td>Antiproliferative restraint</td>
<td>Frequently accompanies apoptosis in colon, lung, breast, and hematologic models.</td>
</tr>
<tr>
<td>5</td>
<td>PI3K Akt ERK STAT growth signaling</td>
<td>↓ PI3K, ↓ Akt, ↓ ERK, ↓ STAT3 (context-dependent)</td>
<td>↔ / cytoprotective inflammatory dampening</td>
<td>R, G</td>
<td>Growth-signaling attenuation</td>
<td>Plausible multi-target effect, but much of the literature is model-specific and extract-dependent.</td>
</tr>
<tr>
<td>6</td>
<td>EMT invasion angiogenesis axis</td>
<td>↓ EMT, ↓ MMP2/9, ↓ CXCR4, ↓ VEGF, ↓ migration / invasion</td>
<td>↔</td>
<td>G</td>
<td>Anti-metastatic phenotype</td>
<td>Consistent preclinical theme; clinically unproven as a direct antimetastatic therapy.</td>
</tr>
<tr>
<td>7</td>
<td>One-carbon metabolism MAT2A</td>
<td>↓ MAT2A activity (AKBA-specific), ↓ SAM flux (context-dependent)</td>
<td>↔ / uncertain</td>
<td>R, G</td>
<td>Metabolic / epigenetic stress</td>
<td>Mechanistically important for AKBA, but direct evidence is strongest outside oncology; relevant as a credible target, not yet a clinically established Boswellia cancer mechanism.</td>
</tr>
<tr>
<td>8</td>
<td>Mitochondrial ROS increase</td>
<td>↑ ROS (context-dependent)</td>
<td>↓ ROS (context-dependent)</td>
<td>R</td>
<td>Redox bifurcation</td>
<td>Cancer-cell oxidative push and normal-tissue antioxidant support can both appear in the literature; this is not a uniformly one-directional axis.</td>
</tr>
<tr>
<td>9</td>
<td>NRF2 antioxidant response</td>
<td>↔ / variable</td>
<td>↑ NRF2, ↑ SOD, ↑ GSH, ↑ catalase (context-dependent)</td>
<td>G</td>
<td>Normal-tissue cytoprotection</td>
<td>More relevant for anti-inflammatory / tissue-protective use than for direct tumor kill; should be treated as secondary, not core, in cancer framing.</td>
</tr>
<tr>
<td>10</td>
<td>Chemosensitization or radiotherapy adjunct</td>
<td>↑ treatment response (context-dependent)</td>
<td>↑ edema control / possible steroid sparing</td>
<td>G</td>
<td>Adjunctive translational utility</td>
<td>Human evidence is strongest for cerebral-edema reduction around brain tumor radiotherapy rather than for proven direct tumor response enhancement.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Low systemic exposure from standard oral extracts</td>
<td>Generally mild GI tolerability profile</td>
<td>G</td>
<td>PK-limited translation</td>
<td>Poor solubility, food dependence, extract heterogeneity, and formulation variability are major reasons preclinical potency does not cleanly translate into established anticancer efficacy.</td>
</tr>
</table>
<p><b>Time-Scale Flag (TSF):</b> P / R / G</p>
<ul>
<li><b>P</b>: 0–30 min (primary/physical–chemical effects; rapid enzymatic/kinase shifts)</li>
<li><b>R</b>: 30 min–3 hr (acute redox + stress-response signaling)</li>
<li><b>G</b>: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)</li>
</ul>